Beigene, LTD Form 4 insider transactions

BeOne Medicines' Global Head of R&D, Wang Lai, sold 5,000 American Depositary Shares for approximately $350.06 per share under a pre-arranged trading plan.

BeOne Medicines Director Corazon Sanders exercised stock options and immediately sold the resulting American Depositary Shares for a significant gain.

BeOne Medicines' Principal Accounting Officer, Titus B. Ball, sold 122 American Depositary Shares to cover tax obligations related to a restricted share unit vesting.

BeOne Medicines Ltd. President and COO Xiaobin Wu exercised stock options and sold a significant number of American Depositary Shares totaling approximately $27 million under a pre-arranged trading plan.

BeOne Medicines' SVP and General Counsel, Chan Henry Lee, executed pre-planned sales of American Depositary Shares following option exercises.

BeOne Medicines' CFO, Aaron Rosenberg, sold 1,190 American Depositary Shares at $290.47 each to cover mandatory tax withholding related to a restricted share unit award.

BeOne Medicines Ltd.'s Global Head of R&D, Wang Lai, executed sales of American Depositary Shares totaling 4,300 units for approximately $1.3 million through a pre-arranged trading plan.

BeOne Medicines' SVP and General Counsel, Lee Chan Henry, sold 920 American Depositary Shares for $304.6008 per share to cover tax withholding obligations related to a restricted share unit award.

BeOne Medicines Ltd.'s Global Head of R&D, Wang Lai, has filed a Form 4 indicating a planned sale of 700 American Depositary Shares on July 18, 2025, executed under a pre-arranged Rule 10b5-1 trading plan.

BeOne Medicines Ltd. CEO and Director John Oyler executed the sale of 27,802 American Depositary Shares (ADSs) on July 9, 2025, as part of a pre-established Rule 10b5-1 trading plan.

BeOne Medicines Ltd.'s Global Head of R&D, Wang Lai, reported a sale of 1,028 American Depositary Shares (ADS) at $260 per share, primarily to cover tax obligations related to the vesting of restricted share units.

BeOne Medicines Ltd.'s President and COO, Xiaobin Wu, sold 1,363 American Depositary Shares for $260 each to cover mandatory tax withholding related to a restricted share unit award.

Xiaodong Wang, a Director and 10% Owner of BeOne Medicines Ltd., executed sales of 2,007 American Depositary Shares (ADS) on June 24, 2025, through a Rule 10b5-1 trading plan.

BeOne Medicines Ltd. CEO John Oyler reported the sale of American Depositary Shares totaling approximately $830,989.96 for mandatory tax withholding purposes related to the vesting of restricted share units.

BeOne Medicines Ltd.'s SVP and General Counsel, Chan Henry Lee, sold 422 American Depositary Shares on June 16, 2025, to cover mandatory tax withholding related to the vesting of restricted share units.

Wang Lai, Global Head of R&D at BeOne Medicines Ltd., reported the sale of American Depositary Shares (ADS) totaling 1,647 units over two days in June 2025, primarily to cover tax withholding obligations related to vested restricted share units.

BeOne Medicines Ltd.'s President and COO, Wu Xiaobin, sold a total of 2,173 American Depositary Shares across two days in June 2025 to cover tax obligations related to the vesting of restricted share units.

BeOne Medicines Ltd. CEO John Oyler reported sales of American Depositary Shares on June 16 and June 17, 2025, primarily to cover mandatory tax withholding obligations related to restricted share unit vesting.

BeOne Medicines' Principal Accounting Officer, Titus B. Ball, reported the acquisition of 29,601 ordinary shares as restricted share units and the sale of 134 American Depositary Shares for tax withholding purposes.

BeOne Medicines Ltd. has granted its Senior Vice President and General Counsel, Lee Chan Henry, a substantial package of restricted share units and share options, aligning executive incentives with long-term company performance.

BeOne Medicines Ltd.'s Chief Financial Officer, Aaron Rosenberg, reported the acquisition of 63,674 restricted share units and 119,873 share options on June 10, 2025, as part of his compensation package.

BeOne Medicines Ltd.'s Global Head of R&D, Wang Lai, has acquired 86,359 restricted share units and 162,565 share options, increasing his direct and indirect beneficial ownership in the company.

BeOne Medicines Ltd. President and COO, Xiaobin Wu, reported the acquisition of over 123,000 restricted share units and 232,000 stock options, alongside the disposition of American Depositary Shares.

A BeOne Medicines Ltd. director and 10% owner, Xiaodong Wang, reported exercising stock options and subsequently selling 41,760 American Depositary Shares (ADSs) for over $10 million, while also receiving new restricted share units and stock options.

BeOne Medicines Ltd. CEO John Oyler has reported the acquisition of 185,055 restricted share units and 348,374 stock options, aligning his incentives with long-term company performance.

BeOne Medicines Ltd. Director Qingqing Yi reported a transfer of 29,614 ordinary shares to funds managed by his employer, disclaiming beneficial ownership.

BeOne Medicines Ltd.'s SVP and General Counsel, Lee Chan Henry, sold 700 American Depositary Shares (ADS) for approximately $179,000 to cover tax obligations related to the vesting of a restricted share unit award.

Wang Lai, Global Head of R&D at BeOne Medicines Ltd., reported the sale of 1,402 American Depositary Shares (ADS) for tax withholding purposes following the vesting of restricted share units.

BeOne Medicines Ltd.'s President and COO, Xiaobin Wu, reported the sale of 1,934 American Depositary Shares (ADS) on June 6, 2025, to cover tax obligations related to the vesting of restricted share units.

BeOne Medicines Ltd. CEO and Director John Oyler reported the sale of 5,127 American Depositary Shares (ADSs) on June 6, 2025, solely to cover tax withholding obligations related to the vesting of a restricted share unit award.